Literature DB >> 18498445

Watermelon stomach in systemic sclerosis: its incidence and management.

I Marie1, P Ducrotte, M Antonietti, S Herve, H Levesque.   

Abstract

BACKGROUND: To date, there are no large endoscopic studies in systemic sclerosis (SSc), and both prevalence and characteristics of watermelon stomach in SSc have not been determined. AIMS: To determine the prevalence, clinical presentation, endoscopic appearance, therapy success and long-term outcome in SSc patients with watermelon stomach and make predictions about which SSc patients are at risk for watermelon stomach. Patients and methods From 1990 to 2008, 264 patients were seen for evaluation of SSc. Data were collected as regards patients' characteristics, time of watermelon stomach onset, features, therapy and outcome of watermelon stomach.
RESULTS: Fifteen SSc patients (5.7%) exhibited watermelon stomach. SSc onset preceded watermelon stomach manifestations in 13 patients (86.7%). Most patients (86.7%) presented with iron-deficiency anaemia, two other patients experienced gastrointestinal haemorrhage. Gastroscopy disclosed typical 'watermelon stomach' characterized by prominent, erythematous stripes, radiating in a spoke-like fashion from the antrum to the pylorus. All patients received conservative therapy; because of deterioration of watermelon stomach, eight patients (53.3%) underwent endoscopic procedures. During follow-up, five patients (33.3%) exhibited recurrences of watermelon stomach.
CONCLUSIONS: Our series indicates that watermelon stomach should be considered when unexplained iron-deficiency anaemia occurs in SSc patients. Moreover, because watermelon stomach may be the first manifestation of SSc, patients with unexplained watermelon stomach should systematically undergo physical examination and autoantibody testing to detect the underlying SSc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18498445     DOI: 10.1111/j.1365-2036.2008.03739.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  21 in total

1.  Cyclophosphamide: a novel treatment of gastric antral vascular ectasia associated with systemic sclerosis?

Authors:  Alicia Peterson; John Varga
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

2.  Management of gastrointestinal involvement in scleroderma.

Authors:  Vivek Nagaraja; Zsuzsanna H McMahan; Terri Getzug; Dinesh Khanna
Journal:  Curr Treatm Opt Rheumatol       Date:  2015-03-01

Review 3.  Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis.

Authors:  S Kumar; J Singh; S Rattan; A J DiMarino; S Cohen; S A Jimenez
Journal:  Aliment Pharmacol Ther       Date:  2017-02-09       Impact factor: 8.171

4.  Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial.

Authors:  Emily W Hung; Maureen D Mayes; Roozbeh Sharif; Shervin Assassi; Victor I Machicao; Chitra Hosing; E William St Clair; Daniel E Furst; Dinesh Khanna; Stephen Forman; Shin Mineishi; Kristine Phillips; James R Seibold; Christopher Bredeson; Mary Ellen Csuka; Richard A Nash; Mark H Wener; Robert Simms; Karen Ballen; Sharon Leclercq; Jan Storek; Ellen Goldmuntz; Beverly Welch; Lynette Keyes-Elstein; Sharon Castina; Leslie J Crofford; Peter Mcsweeney; Keith M Sullivan
Journal:  J Rheumatol       Date:  2013-02-15       Impact factor: 4.666

5.  Gastric antral vascular ectasia in systemic sclerosis: Association with anti-RNA polymerase III and negative anti-nuclear antibodies.

Authors:  Naomi Serling-Boyd; Melody Pei-Shien Chung; Shufeng Li; Laren Becker; Nielsen Fernandez-Becker; John Clarke; David Fiorentino; Lorinda Chung
Journal:  Semin Arthritis Rheum       Date:  2020-07-06       Impact factor: 5.532

Review 6.  Gastrointestinal and Hepatic Disease in Systemic Sclerosis.

Authors:  Tracy M Frech; Diane Mar
Journal:  Rheum Dis Clin North Am       Date:  2018-02       Impact factor: 2.670

Review 7.  Microvascular involvement in systemic sclerosis and systemic lupus erythematosus.

Authors:  Didem Saygin; Kristin B Highland; Adriano R Tonelli
Journal:  Microcirculation       Date:  2019-04       Impact factor: 2.628

Review 8.  Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management.

Authors:  Genevieve Gyger; Murray Baron
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

9.  Radiofrequency ablation for patients with refractory symptomatic anaemia secondary to gastric antral vascular ectasia.

Authors:  Cormac Magee; Gideon Lipman; Durayd Alzoubaidi; Martin Everson; Rami Sweis; Matthew Banks; David Graham; Charles Gordon; Laurence Lovat; Charles Murray; Rehan Haidry
Journal:  United European Gastroenterol J       Date:  2018-11-15       Impact factor: 4.623

10.  Clinical Assessment of Gastrointestinal Involvement in Patients with Systemic Sclerosis.

Authors:  Timothy Kaniecki; Tsion Abdi; Zsuzsanna H McMahan
Journal:  Med Res Arch       Date:  2020-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.